The Journal of Immunology, Vol 155, Issue 1 339-347, Copyright © 1995 by American Association of Immunologists

ARTICLES

Antigen-based heteropolymers facilitate, via primate erythrocyte complement receptor type 1, rapid erythrocyte binding of an autoantibody and its clearance from the circulation in rhesus monkeys

PJ Ferguson, EN Martin, KL Greene, S Kuhn, DS Cafiso, G Addona and RP Taylor
Department of Pediatrics, University of Virginia School of Medicine, Charlottesville 22908, USA.

We investigated the feasibility of using the primate E complement receptor (CR1), in concert with Ag-based heteropolymers (AHP), as a potential therapy to remove autoantibodies from the circulation. AHP are prepared by cross-linking an anti-CR1 mAb with the acetylcholine receptor (AChR), the principal target Ag in myasthenia gravis. In vitro studies demonstrate that this methodology facilitates specific, rapid, and quantitative binding of an anti-AChR mAb to primate Es. In vivo experiments in rhesus monkeys indicate that AHP-mediated binding of an anti-AChR mAb to Es leads to the clearance of the mAb from the circulation. Once bound to the E via the AHP, the autoantibody is transported to the liver and spleen, where it is degraded without destruction of the E. It is therefore likely that the complexes of AHP and target mAb, when bound to Es, are recognized in vivo and processed by a mechanism quite similar to that which occurs when complement- opsonized immune complexes, bound to primate Es, are cleared from the circulation. It may be possible to extend and generalize this work to allow for the development of a simple, noninvasive therapy that can be made specific for the treatment of several different autoimmune diseases.

This article has been cited by other articles:

				A. W. Pawluczkowycz, M. A. Lindorfer, J. N. Waitumbi, and R. P. Taylor Hematin Promotes Complement Alternative Pathway-Mediated Deposition of C3 Activation Fragments on Human Erythrocytes: Potential Implications for the Pathogenesis of Anemia in Malaria J. Immunol., October 15, 2007; 179(8): 5543 - 5552. [Abstract] [Full Text] [PDF]

				S. Zaitsev, K. Danielyan, J.-C. Murciano, K. Ganguly, T. Krasik, R. P. Taylor, S. Pincus, S. Jones, D. B. Cines, and V. R. Muzykantov Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis Blood, September 15, 2006; 108(6): 1895 - 1902. [Abstract] [Full Text] [PDF]

				T. M. Aune, A. L. Mora, S. Kim, M. Boothby, and A. H. Lichtman Costimulation Reverses the Defect in IL-2 But Not Effector Cytokine Production by T Cells with Impaired I{kappa}B{alpha} Degradation J. Immunol., May 15, 1999; 162(10): 5805 - 5812. [Abstract] [Full Text] [PDF]

				S. E. Kuhn, A. Nardin, P. E. Klebba, and R. P. Taylor Escherichia coli Bound to the Primate Erythrocyte Complement Receptor via Bispecific Monoclonal Antibodies Are Transferred to and Phagocytosed by Human Monocytes in an In Vitro Model J. Immunol., May 15, 1998; 160(10): 5088 - 5097. [Abstract] [Full Text] [PDF]

				S. C. Makrides Therapeutic Inhibition of the Complement System Pharmacol. Rev., March 1, 1998; 50(1): 59 - 88. [Abstract] [Full Text] [PDF]

				M. L. Reinagel, M. Gezen, P. J. Ferguson, S. Kuhn, E. N. Martin, and R. P. Taylor The Primate Erythrocyte Complement Receptor (CR1) as a Privileged Site: Binding of Immunoglobulin G to Erythrocyte CR1 Does Not Target Erythrocytes for Phagocytosis Blood, February 1, 1997; 89(3): 1068 - 1077. [Abstract] [Full Text] [PDF]